Tonix Pharmaceuticals Holding Corp. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Tonix received positive Type C FDA meeting minutes for TNX-4800, an anti-OspA monoclonal antibody to prevent Lyme disease. FDA agreed on adaptive Phase 2 field study design enrolling ~3,300 adult participants randomized 1:1 to TNX-4800 450mg SC or placebo, dosed two months apart, with primary efficacy endpoint of Lyme disease prevention through six months. Study manufacturing on track for Q1 2027 start, with majority enrollment expected in 2028 season.
Why this rating
Regulatory alignment de-risks clinical pathway for promising pipeline asset in large unmet need market (87M at-risk Americans). Phase 2 has efficacy potential. Modest fraction of $271M market cap; near-term value depends on enrollment success.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.